4-acetylmorpholine

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1967-03-22 to 1967-04-05

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study predating guidelines and GLP, but meeting the principles of OECD TG 401.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1967

Report date:

1967

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Version / remarks:

(Study predating Guideline)

Deviations:

not applicable

Principles of method if other than guideline:

Method: other: BASF test

GLP compliance:

no

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

4-acetylmorpholine

EC Number:

216-913-4

EC Name:

4-acetylmorpholine

Cas Number:

1696-20-4

Molecular formula:

C6H11NO2

IUPAC Name:

1-(morpholin-4-yl)ethan-1-one

Details on test material:

- Name of test material: N-Acetylmorpholin

Test animals

Species:

rat

Strain:

other: "US-rats"

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: 166 - 280 g (males); 156 - 200 g (females)

ENVIRONMENTAL CONDITIONS
- no data

IN-LIFE DATES: From: 1967-03-29 To: 1967-04-05

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: aqueous tragacanth emulsion

Details on oral exposure:

VEHICLE
- Vehicle concentration: 30% (6400, 3200 mm3/kg bw) , 20% (1600 mm3/kg bw), 2% (200 mm3/kg bw)

MAXIMUM DOSE VOLUME APPLIED:
21, 3 mL / kg

Doses:

6400, 3200, 1600 or 200 mm3 / kg bw, corresponds to:
7136, 3568, 1784 or 223 mg / kg bw ; calculation based on density of test item

No. of animals per sex per dose:

5 males and 5 females

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: body weight taken at study start only for dose determination, but not reported
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs monitored but frequency unknown, gross necropsy on fatalities

Statistics:

not performed

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 7 136 mg/kg bw

Based on:

test mat.

Remarks on result:

other: Liquid: calculation based on density

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 6.4 mL/kg bw

Based on:

test mat.

Mortality:

6400 mm3 / kg bw: 3/10 (1/10 within 24 h, 2/10 within 48 h)
3200 mm3 / kg bw: 0/10
1600 mm3 / kg bw: 1/10 (between day 2 and day 7)
200 mm3 / kg bw: 0/10

Clinical signs:

other: 3200 and 6400 mm3 / kg bw: Laboured breathing, hunched posture, ptosis, red crust around eyes and snout, mild apathy, ruffled fur (on day of dosing, surviving animals recuperated)

Gross pathology:

Chronic bronchitis and brochiectasis (10x, non test item related)
Perished animals: bloated stomach (2x), bloated gut (1x), pallid liver (1x)

Other findings:

None